Open AccessSuppression of Gonadotropins and Estradiol in Premenopausal Women by Oral Administration of the Nonpeptide Gonadotropin-Releasing Hormone Antagonist Elagolix
Author(s) -
R. Scott Struthers,
Andrew Nicholls,
John S. Grundy,
Takung Chen,
Roland Jimenez,
S. S. C. Yen,
Haig Bozigian
Publication year - 2009
Publication title -
the journal of clinical endocrinology and metabolism/journal of clinical endocrinology and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2008-1695
Subject(s) - medicine , endocrinology , placebo , tolerability , hormone antagonist , pharmacokinetics , oral administration , hormone , antagonist , follicular phase , endocrine system , gonadotropin , gonadotropin releasing hormone antagonist , gonadotropin releasing hormone , luteinizing hormone , adverse effect , receptor , alternative medicine , pathology
Parenteral administration of peptide GnRH analogs is widely employed for treatment of endometriosis and fibroids and in assisted-reproductive therapy protocols. Elagolix is a novel, orally available nonpeptide GnRH antagonist.